Kazuo Mishima
Overview
Explore the profile of Kazuo Mishima including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
171
Citations
1804
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aoki R, Miyachi T, Sugano Y, Kanke C, Yamazaki T, Mishima K, et al.
J Occup Health
. 2025 Feb;
PMID: 39960452
Objectives: This study aimed to investigate how many drivers would have sleep disorders and what factors would be most associated with chronic insomnia symptoms. Methods: A cross-sectional study of 505...
2.
Ukai M, Hida A, Kitamura S, Inoue Y, Mishima K
Sleep
. 2025 Jan;
48(3).
PMID: 39786455
No abstract available.
3.
Funaki M, Noguchi A, Ishikawa H, Noutomi R, Fukuda K, Shimazu K, et al.
Jpn J Clin Oncol
. 2025 Jan;
PMID: 39756803
Familial adenomatous polyposis (FAP) is an inherited disorder that follows an autosomal dominant inheritance pattern and is caused by a germline pathogenic variant in the APC gene. FAP also has...
4.
Komatsu M, Takeshima M, Yoshizawa K, Ogasawara M, Kudo M, Miyakoshi E, et al.
Front Psychiatry
. 2024 Dec;
15:1471457.
PMID: 39717375
Introduction: Hypnotic polypharmacy and its long-term prescriptions constitute the inappropriate use of hypnotics. However, the relationship between hypnotic polypharmacy and prolonged prescriptions remains unclear. This study aimed to elucidate the...
5.
Irinaka K, Itoh Y, Yoshizawa K, Ogasawara M, Ayabe N, Mishima K, et al.
Clin Psychopharmacol Neurosci
. 2024 Oct;
22(4):688-696.
PMID: 39420617
Tardive dyskinesia and dystonia are intractable extrapyramidal symptoms caused by the blockade of dopamine receptors by antipsychotic drugs. In addition to the reduction or discontinuation of the causative drug, valbenazine...
6.
Tanaka-Mizuno S, Fujimoto K, Mishima K, Sakata Y, Fukasawa T, Mizuno K, et al.
Expert Opin Pharmacother
. 2024 Aug;
25(12):1707-1716.
PMID: 39129520
Background: When considering changing hypnotic pharmacotherapy, lemborexant has attracted attention as a candidate due to its effectiveness and safety profile. However, few studies have investigated switching patterns in clinical practice....
7.
Gotfried M, Auerbach S, Dang-Vu T, Mishima K, Kumar D, Moline M, et al.
Drugs Aging
. 2024 Aug;
41(9):741-752.
PMID: 39120786
Background: Insomnia is more common as people age. Several common hypnotics used to treat insomnia often do not adequately alleviate sleep issues in older adults and may be associated with...
8.
Uchiyama M, Mishima K, Yagi T, Yoshihara T, Eto T, Muehlan C, et al.
J Sleep Res
. 2024 Aug;
34(1):e14302.
PMID: 39118245
Daridorexant is a dual orexin receptor antagonist for the treatment of insomnia. We report results from the first two randomised, double-blind clinical studies of daridorexant in Japanese subjects. In the...
9.
Takeshima M, Yoshizawa K, Ogasawara M, Kudo M, Itoh Y, Ayabe N, et al.
Front Psychiatry
. 2024 Jul;
15:1405049.
PMID: 39026522
Introduction: Guidelines for various psychiatric disorders recommend short-term use of benzodiazepine anxiolytic monotherapy in few cases. Contrarily, benzodiazepine anxiolytic polypharmacy (BAP) is not recommended in any case. However, BAP is...
10.
Takeshima M, Yoshizawa K, Ogasawara M, Kudo M, Itoh Y, Ayabe N, et al.
Psychogeriatrics
. 2024 Jul;
24(5):1176-1179.
PMID: 39010736
No abstract available.